This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Specifid

MMR Information Systems, Inc.

Drug Names(s): Id/KLH, Mitumprotimut-T, FavId

Description: FavId is based upon unique genetic information extracted from a patient's tumor. The process starts by taking an individuals tumor biopsy and identifying the unique idiotype genes present in the tumor. These tumor-specific genes are then used to manufacture a recombinant, patient-specific protein in a non-mammalian cell system. Once purified, the patient-specific protein is formulated by conjugating it to a large immunostimulatory protein called KLH. This product, termed FavId, is combined with GM-CSF, a natural immune system growth factor, to enhance its immunostimulatory property prior to injecting this patient-specific therapy back into the patient. The process from biopsy to treatment takes just under three months.

Deal Structure: FavId was originally developed by Favrille.

In February 2007, Favrille announced that it entered into an agreement with Berlex, a U.S. affiliate of Bayer Schering. While terms of the agreement were not disclosed, the focus of the agreement will be on studying the use of FavId (Id/KLH) in conjunction with Berlex's growth factor Leukine (sargramostim, GM-CSF) in patients with B-cell non-Hodgkin's lymphoma (NHL).


Specifid News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug